U.S. market Closed. Opens in 7 hours 35 minutes

HARP | Harpoon Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 22.99 - 23.02
52 Week Range 3.11 - 23.21
Beta 2.25
Implied Volatility 124.72%
IV Rank 0.28%
Day's Volume 6,401,494
Average Volume 1,129,503
Shares Outstanding 37,595,800
Market Cap 865,079,358
Sector Healthcare
Industry Biotechnology
IPO Date 2019-02-08
Valuation
Profitability
Growth
Health
P/E Ratio -15.04
Forward P/E Ratio N/A
EPS -1.53
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 45
Country USA
Website HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
HARP's peers: ADAP, ADCT, ALEC, BDTX, CABA, CRNX, DARE, DTIL, ETON, GOSS, NKTX, QSI, STOK, SYRS, TCRT
*Chart delayed
Analyzing fundamentals for HARP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see HARP Fundamentals page.

Watching at HARP technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on HARP Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙